cure for cancer ! & still 1.7 cents !, page-57

"Benitec, an Australian gene therapy biotech company, who is looking for institutional investors with expertise in the biotech space to take substantial holdings of at least 5%"

D, here is advice from a venture capitalist and some of what he says seems very familiar.

http://www.xconomy.com/san-francisco/2013/01/23/venbios-goodman-builds-an-inside-periscope-on-biotech-acquisitions/

If we think of BLT as a start-up, albeit already a public company with public investors, he says,

“A lot of companies got created [in the 90's] with the thinking, ‘If you build it they will come,’ ” Goodman says. But the flush times receded as the financial returns from many companies fell short, he says. A shakeout among life sciences venture firms followed, as IPO exits became fewer and leaner. These days, startups and their investors should be setting their sights on an acquisition by a larger pharmaceutical or biotechnology company, not an IPO, Goodman says. And to do that, they have to figure out what those larger companies want.

I am still scratching my head to know what our strategy is.